Elizabeth A Woodcock

List of Publications by Year
in descending order

17 papers	5,440 citations	840776 11 h-index	940533 16 g-index
17 all docs	17 docs citations	17 times ranked	14109 citing authors

#	Article	IF	Citations
1	Expressing an inhibitor of PLCÎ²1b sustains contractile function following pressure overload. Journal of Molecular and Cellular Cardiology, 2016, 93, 12-17.	1.9	3
2	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
3	Chronic Contractile Dysfunction without Hypertrophy Does Not Provoke a Compensatory Transcriptional Response in Mouse Hearts. PLoS ONE, 2016, 11, e0158317.	2.5	3
4	Novel Therapeutic Targets in Heart Failure: The Phospholipase CÎ²1bâ€“Shank3 Interface. Clinical Medicine Insights Therapeutics, 2015, 7, CMT.S18480.	0.4	2
5	Phospholipase CÎ²1b directly binds the SH3 domain of Shank3 forÂtargeting and activation in cardiomyocytes. Biochemical and Biophysical Research Communications, 2015, 461, 519-524.	2.1	6
6	The atypical â€˜bâ€™ splice variant of phospholipase CÎ²1 promotes cardiac contractile dysfunction. Journal of Molecular and Cellular Cardiology, 2015, 84, 95-103.	1.9	11
7	The Phosphatidylinositol(4,5)Bisphosphateâ€“Binding Sequence of Transient Receptor Potential Channel Canonical 4Î± Is Critical for Its Contribution to Cardiomyocyte Hypertrophy. Molecular Pharmacology, 2014, 86, 399-405.	2.3	10
8	No Contribution of IP 3 -R(2) to Disease Phenotype in Models of Dilated Cardiomyopathy or Pressure Overload Hypertrophy. Circulation: Heart Failure, 2013, 6, 318-325.	3.9	17
9	Scaffolding protein Homer 1c mediates hypertrophic responses downstream of Gq in cardiomyocytes. FASEB Journal, 2012, 26, 596-603.	0.5	21
10	Phospholipase CÎ²lb associates with a Shank3 complex at the cardiac sarcolemma. FASEB Journal, 2011, 25, 1040-1047.	0.5	30
11	Gqâ€initiated cardiomyocyte hypertrophy is mediated by phospholipase CÎ²1b. FASEB Journal, 2009, 23, 3564-3570.	0.5	78
12	Selective activation of the â€œbâ€•splice variant of phospholipase CÎ²1 in chronically dilated human and mouse atria. Journal of Molecular and Cellular Cardiology, 2009, 47, 676-683.	1.9	29
13	Phosphoinositide signalling and cardiac arrhythmias. Cardiovascular Research, 2008, 82, 286-295.	3.8	35
14	The extreme Câ€terminal region of phospholipase CÎ²1 determines subcellular localization and function; the â€œbâ€•splice variant mediates Î±₁â€adrenergic receptor responses in cardiomyocytes. FASEB Journal, 2008, 22, 2768-2774.	0.5	45
15	Protective effects of exercise and phosphoinositide 3-kinase(p110Â) signaling in dilated and hypertrophic cardiomyopathy. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 612-617.	7.1	269
16	Evidence for Selective Coupling of Î±1-Adrenergic Receptors to Phospholipase C-Î²1 in Rat Neonatal Cardiomyocytes. Journal of Biological Chemistry, 2001, 276, 37341-37346.	3.4	50
17	Î² ₂ -Adrenergic Receptor Overexpression Exacerbates Development of Heart Failure After Aortic Stenosis. Circulation, 2000, 101, 71-77.	1.6	130